Oncology - CurrentMed (Page 5)

Oncology

EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis

PMCID: PMC12174314 PMID: 40527884 DOI: 10.1038/s41419-025-07771-1 Journal: Cell death & disease Publication Date: 2025-6-17 Authors: Yuan F, Wang Y, Yuan L, Tang T, Ye L, et al. Key Points * EGFRvIII mutation is associated with higher WHO grade 4 gliomas (93.3% vs. 53.6%, p=0.044) * M2

Oncology

The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma

PMCID: PMC12178006 PMID: 40533802 DOI: 10.1186/s12967-025-06704-y Journal: Journal of translational medicine Publication Date: 2025-6-18 Authors: Zhou X, Cui G, Hu E, Wang X, Tang D, et al. Key Points * A six-gene DNL signature effectively stratifies HCC patients into distinct prognostic risk groups * Predictive model shows high accuracy with

Oncology

ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer

PMCID: PMC12175430 PMID: 40528239 DOI: 10.1186/s13046-025-03435-2 Journal: Journal of experimental & clinical cancer research : CR Publication Date: 2025-6-18 Authors: Xu K, Chen H, Zhu X, Li H, Liu X, et al. Key Points * High ESRP1 expression is an independent prognostic factor for improved survival in diffuse-type gastric cancer

Pharmacology

[18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial

PMCID: PMC12175455 PMID: 40528226 DOI: 10.1186/s13063-025-08921-8 Journal: Trials Publication Date: 2025-6-17 Authors: Ruijters VJ, Snijders TJ, van der Pol JA, van de Giessen EM, Niers JM, et al. Key Points * First comprehensive randomized trial investigating FET PET's utility in differentiating pseudoprogression from true tumor progression in

Oncology

N6-methyladenosine-modified GPX2 impacts cancer cell stemness and TKI resistance through regulating of redox metabolism

PMCID: PMC12177039 PMID: 40533443 DOI: 10.1038/s41419-025-07764-0 Journal: Cell death & disease Publication Date: 2025-6-18 Authors: Yang X, Yu L, Shao M, Yang H, Qi K, et al. Key Points * GPX2 serves as a critical mediator of EGFR-TKI resistance in NSCLC by modulating cellular redox balance * Knockdown of GPX2

Gastroenterology

The Effect of Postoperative Antithrombin Supplementation on the Inflammatory and Coagulation Status of a Surgically Treated Patient With a Malignant Tumor in the Small Pelvis—Case Series

PMCID: PMC12177226 PMID: 40534446 DOI: 10.1002/cnr2.70260 Journal: Cancer reports (Hoboken, N.J.) Publication Date: 2025-6-19 Authors: Lazović R, Šarenac O Key Points * Antithrombin supplementation can effectively normalize coagulation and inflammatory responses in complex surgical patients * Observed 50-70% reduction in inflammatory markers (IL-6, CRP) within 4 postoperative days

Gastroenterology

Impeding Quorum Sensing Among the Intestinal Microbiota Impacts the Metastatic Rate of Colorectal Cancer

PMCID: PMC12177794 PMID: 40536191 DOI: 10.1002/cam4.71009 Journal: Cancer medicine Publication Date: 2025-6-19 Authors: Dietz M, Gates TJ, Sikdar R, Subramanian S, Elias MH, et al. Key Points * QQ lactonase treatment demonstrated sex-specific effects on CRC metastasis * Male mice treated with SsoPox showed 0% metastasis compared to 30%

Immunology

Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia

PMCID: PMC12173385 PMID: 40526635 DOI: 10.1371/journal.pone.0324443 Journal: PloS one Publication Date: 2025-6-17 Authors: Vrana C, Zhang M, Rochette M, Alozie M, Oviedo H, et al. Key Points * NAMPT inhibition represents a promising targeted therapeutic approach for T-ALL * FK866 increased median survival by 39.5 days in

Oncology

Thermal ablation for pulmonary oligometastases from hepatocellular carcinoma: initial experience and retrospective study

PMCID: PMC12177983 PMID: 40533817 DOI: 10.1186/s40644-025-00896-8 Journal: Cancer imaging : the official publication of the International Cancer Imaging Society Publication Date: 2025-6-18 Authors: Hou R, Zhou X, Li Y, Qin Y, Song M, et al. Key Points * Thermal ablation achieved 100% technical success with 96.8% technical efficacy in

Immunology

CAR‐NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor

PMCID: PMC12171998 PMID: 40525700 DOI: 10.1002/iid3.70210 Journal: Immunity, inflammation and disease Publication Date: 2025-6-17 Authors: Cao Y, Wang L, Wang L Key Points * CAR-NK cells provide a safer, more adaptable immunotherapy alternative to CAR-T cells * Potential for "off-the-shelf" manufacturing reduces personalization complexity and treatment time

Gastroenterology

Establishing high risk factors for recurrence in stage I/II colorectal cancer: a metropolitan perspective

PMCID: PMC12175440 PMID: 40533762 DOI: 10.1186/s12957-025-03823-0 Journal: World journal of surgical oncology Publication Date: 2025-6-18 Authors: Wood PC, Zammit AP, Ferris B, Simpson FH, Burge M, et al. Key Points * Overall recurrence rate of 13.3% in early-stage CRC, with stage II patients at higher risk * Venous invasion,

Oncology

Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors

PMCID: PMC12177888 PMID: 40392078 DOI: 10.1530/ERC-25-0052 Journal: Endocrine-related cancer Publication Date: 2025-6-18 Authors: Siebenhüner AR, Refardt J, Nicolas GP, Kaderli R, Walter MA, et al. Key Points * MKIs represent a significant advancement in GEP-NET treatment, offering improved progression-free survival across multiple tumor subtypes * Median PFS improvements range from